Chelmsford’s Magellan Biosciences has acquired TekCel, a Hopkinton-based maker of sample-management and assay-automation systems for biomedical research. Terms of the transaction were not disclosed.

TekCel employs approximately 35 people, all of whom are expected to remain with the company, according to Magellan.

According to Robert J. Rosenthal, president and chief executive officer of Magellan, the acquisition of TekCel and its product line will allow the company to reach a market beyond the smaller enterprises.

Founded in 1998, TekCel’s modular, scalable family of products includes sample-management automation, liquid handling, software, and proprietary consumables addressing the researchers’ needs from archive compound storage through screening result.

Magellan Biosciences develops advanced instruments, automated systems, point-of-care products, and consumables for biomedical research and clinical diagnostics.

Boston Mass High Tech, MA